Smith Group Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Smith Group Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,967	Closed	-$92K	–	450
2018 Q3	$92K	Hold	20,967	–	–	﹤0.01%	276
2018 Q2	$129K	Hold	20,967	–	–	﹤0.01%	267
2018 Q1	$153K	Sell	20,967 -733	-3%	-$6.45K	0.01%	271
2017 Q4	$178K	Hold	21,700	–	–	0.01%	266
2017 Q3	$228K	Sell	21,700 -710	-3%	-$6.78K	0.01%	254
2017 Q2	$247K	Sell	22,410 -10,180	-31%	-$102K	0.01%	259
2017 Q1	$315K	Hold	32,590	–	–	0.01%	222
2016 Q4	$339K	Buy	32,590 +2,160	+7%	+$23.7K	0.01%	214
2016 Q3	$377K	Buy	30,430 +650	+2%	+$8.49K	0.01%	201
2016 Q2	$320K	Buy	+29,780	New	+$318K	0.01%	217

Other funds holding AVDL

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Smith Group Asset Management's AVDL Position: Q4 2018 in Review

Smith Group Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2018, closing a stake of 20,967 shares — an estimated $92K sold.

Smith Group Asset Management first reported a position in AVDL in Q2 2016 and held it in 10 quarters. The position peaked at $377K in Q3 2016. 59 funds tracked by Wall St. Rank hold AVDL as of Q4 2018.

Smith Group Asset Management reported no remaining Avadel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Smith Group Asset Management sold 20,967 Avadel Pharmaceuticals shares in Q4 2018, an estimated $92K.
Smith Group Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2016 and held it in 10 quarters.
Smith Group Asset Management's Avadel Pharmaceuticals position peaked at $377K in Q3 2016.
59 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2018.

Based on Smith Group Asset Management's 13F filing for Q4 2018, filed 6 Feb 2019.